Author name: Don Mccaughey

February 14, 2024 in Supplier News, Vendor Content   Barbell training has long reigned supreme for building strength and muscle, offering versatility and adaptability for all fitness levels. But limitations like awkward setup, safety concerns and space constraints have limited even wider consumer adoption. Introducing the GYM RAX SMITH 3D Trainer(S3D) from Aktiv Solutions — an evolutionary advancement in free-weight training systems designed to welcome the surging population of strength training enthusiasts. The SMITH 3D Trainer seamlessly blends the advantages of free weight training with the safety and versatility of its unique, patent-pending design. Unlike traditional smith machines, the S3D mimics the natural movement patterns of barbell exercises without the restrictions of a single and linear range of motion. Seasoned lifters and beginners alike can push their limits with confidence thanks to the synchronized safety catches that act as a built-in “spotter.” Key Features: 3D Movement: Replicates the natural flow and movement pattern of free weights for optimal muscle activation. Enhanced Safety: Synchronized safety catches allow for “self-spotting” throughout the entire exercise. Ideal for unsupervised facilities including large health clubs, fitness amenities and student recreation centers. Space-Saving Design: The S3D compact footprint maximizes gym space without the requirement of additional lifting platforms. Versatility: Flow seamlessly through a wide range of barbell exercises with control and power. “The world is recognizing the transformative power of strength training, from boosting longevity and mobility to enhancing overall quality of life,” said Bryan Green, the CEO of Aktiv Solutions. “Very few tools compete with the natural movement and effectiveness of the barbell. With the S3D, we’ve now unlocked unprecedented levels of efficiency, safety and user experience, making barbell training accessible for everyone, regardless of their fitness level or goals.” Say goodbye to the limitations of traditional barbell training. Contact Aktiv today to elevate the free-weight training experience at your facility with the extraordinary SMITH 3D Trainer. Learn more about the SMITH 3D Trainer at aktivsolutions.com/gym-rax/smith3dtrainer/.  

VANCOUVER, BC, Jan. 22, 2024 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, presented positive Phase 2 safety and efficacy data in advanced metastatic colorectal cancer (mCRC) patients treated with BOLD-100 in combination with FOLFOX previously treated with FOLFOX/CAPOX at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium on January 18-20, 2024. Bold Therapeutics Inc. Bold Therapeutics’ BOLD-100 is a first-in-class metallotherapeutic with a unique multimodal mechanism-of-action that targets a critical replication and survival pathway common across all cancers. Interim results presented at AACR (April 2023) and ASCO (June 2023) showed robustly positive efficacy and safety results in advanced colorectal, biliary tract and gastric cancer patients.   Bold Therapeutics’ ongoing BOLD-100-001 (NCT04421820) study is a multinational Phase 2 clinical trial evaluating BOLD-100 in combination with standard-of-care FOLFOX (folinic acid / leucovorin, fluorouracil, and oxaliplatin) in patients with advanced gastrointestinal cancers. The trial has currently enrolled 109 patients with advanced biliary tract, colorectal, gastric, and pancreatic cancers at sites in Canada, the United States, Ireland, and South Korea. The primary endpoint for the trial is progression-free survival (PFS), with overall survival (OS) and objective response rate (ORR) as secondary endpoints. Disease control rate (DCR) was also captured. As of an August 31, 2023 data cutoff, data from 36 patients with advanced metastatic colorectal cancer was presented in clinical poster format (abstract #143) entitled “BOLD-100-001 (TRIO039): A Phase 2 Study of BOLD-100 in Combination with FOLFOX in Advanced mCRC Patients Previously Treated with FOLFOX/CAPOX: Efficacy and Safety Analysis.” Key findings: Enrolled patients had a median of 4 [range 2-8] prior therapies including FOLFOX/CAPOX 67% of patients had progressive disease on prior FOLFOX/CAPOX Median progression-free survival (PFS) was 3.9 months [CI 2.7, 5.7] Median overall survival (OS) was 9.6 months [CI 6.0, 17] In 29 evaluable patients for response, the objective response rate (ORR) was 7.0%, with 2 partial responses (PR) and 20 stable diseases (SD) resulting in a disease control rate (DCR) of 76% These findings indicate a clinical benefit for patients treated with BOLD-100 in combination with FOLFOX and on all metrics compares favorably to existing treatment options for advanced metastatic colorectal cancer: Taiho’s Lonsurf® (trifluridine / tipiracil), Bayer’s Stivarga® (regorafenib), and Takeda’s Fruzaqla® (fruquintinib). The table below compares this data against the data from the registration studies for these existing treatment options, all of which had less progressed (and thus healthier) patient populations. BOLD-100 in combination with FOLFOX continued to be well-tolerated, with no new safety signals. For all treated patients, treatment-emergent adverse events (TEAEs) were observed in 33 (92%) of patients, with the most common TEAEs as follows: neutrophil count decreases (all grade 47%, grade ≥3 42%), nausea (42%, grade ≥3 0%), and fatigue (19%, grade ≥3 0%). “Not only are we encouraged with BOLD-100’s efficacy, but we are excited about BOLD-100’s unexpectedly favorable safety profile, which has allowed patients to remain on treatment considerably longer than originally expected and thus maximizes the impact of the treatment combination,” noted Jim Pankovich, EVP of Clinical Development. “More specifically, relatively few patients in our study experienced neurotoxicity, despite all patients having been previously treated with neurotoxicity-inducing oxaliplatin.” Phase 2 safety and efficacy results in biliary tract and gastric cancer are currently available under confidentiality and will be presented publicly at a major cancer conference later this year. “Bold Therapeutics was founded in 2018 to improve patient outcomes in some of the most difficult-to-treat cancer indications and has rapidly progressed since then” added E. Russell McAllister, CEO. “We look forward to initiating late-stage studies in the near-future, initially targeting a 2027 FDA approval in advanced metastatic colorectal cancer.” For more information, please visit the Company’s website at https://www.bold-therapeutics.com/ Contact: E. Russell McAllister, CEO371735@email4pr.com+1 (604) 262-9899 SOURCE Bold Therapeutics Inc.

International Health and Safety Franchise Stands Out in the Commercial Cleaning Industry CHARLOTTE, NC / ACCESSWIRE / September 29, 2023 / Enviro-Master, the nation’s premier health and safety franchise company, is proud to announce its inclusion on the Franchise Times Top 400 List. As a testament to its unwavering commitment to excellence, the brand has solidified its position as a top performer in the commercial cleaning services sector. The list ranks 400 franchise-based businesses based on their systemwide sales from the previous year. With global sales surpassing $95 million in 2022, Enviro-Master has secured the 337th spot. “We’re absolutely thrilled to be recognized on this esteemed list,” expresses Tod Bierling, CEO of Enviro-Master Services. “Our growth and success are a testament to the incredible entrepreneurs within our network. With 100 locations spanning North America, our team is dedicated to delivering top-notch commercial cleaning and disinfecting services.” Since its inception in 2009, businesses worldwide have entrusted Enviro-Master with their health and safety needs. The company’s comprehensive suite of services includes the commercial restroom cleaning program, commercial tile and grout cleaning, drain treatment, and the unique Virus Vaporizer™ electrostatic spraying protection service. Enviro-Master also offers paper restocking and hand sanitizer services. The recent introduction of the Re-Fresh Commercial Power Washing and RPM Commercial Window Cleaning services further underscores the brand’s commitment to innovation. By expanding its service offerings, Enviro-Master solidifies its position as a one-stop shop for holistic health and safety solutions, further cementing its reputation as an industry trailblazer. The Franchise Times Top 400 is an exclusive annual ranking that showcases the largest United States-based franchise systems based on global systemwide sales. This prestigious list is the culmination of rigorous research and reporting, ensuring its status as the most credible and objective franchise ranking available. About Enviro-Master: Enviro-Master is a leading health and safety franchise company specializing in comprehensive solutions for businesses nationwide. With a commitment to cleanliness, hygiene, and environmental sustainability, Enviro-Master delivers a range of services, including commercial power washing, commercial window cleaning, and commercial restroom hygiene, to promote safe and healthy business environments. To learn more about franchising opportunities with Enviro-Master, visit https://enviro-master.com/commercial-cleaning-franchises/. Media Contact: Tammy Delgado tdelgado@919marketing.com SOURCE: Enviro-Master

VANCOUVER, BC, September 14, 2023 – Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, is announcing its selection by Life Sciences British Columbia (LSBC) for the 2023 ‘Company to Watch’ Honour Roll. This year marks the 25th Annual Life Sciences BC Awards that brings together industry leaders, researchers, investors, and stakeholders to celebrate their remarkable achievements. The ceremony will provide an opportunity to showcase the cutting-edge research, technological advancements, and collaborations that drive innovation in British Columbia’s thriving life sciences community and takes place on September 14, 2023 at the Vancouver Convention Centre. “Following an exciting 2023 and positioned for a potentially even more exciting 2024, we are honored to be recognized by our peers as a ‘Company to Watch’ by LSBC,” said E. Russell McAllister, President and CEO of Bold Therapeutics. “This recognition reflects the rapid progress we have made since our founding in June 2018, as well as the recent clinical success of our lead compound, BOLD-100, with positive proof-of-concept data in the treatment of not just one, but three different difficult-to-treat gastrointestinal cancer indications: colorectal, biliary tract and gastric. It also speaks to the potentially life-changing impact BOLD-100 could have on patient outcomes in the future. This has truly been a team effort, and I want to recognize my friends and colleagues, Jim Pankovich, EVP of Clinical Development, Mark Bazett, Senior Director of Preclinical Development, Michelle Jones, Senior Director of Clinical Development, and Glenn Walthall, Chairman of the Board and CIO of Gaston Capital Partners, our lead investor, whose combined efforts and leadership over the past five years have allowed us to reach this important milestone.” Bold Therapeutics’ BOLD-100 is a first-in-class metallotherapeutic with a unique multimodal mechanism-of-action. Interim results presented at AACR (April 2023) and ASCO (June 2023) showed robustly positive efficacy and safety results in advanced colorectal, biliary tract and gastric cancer patients, with clear advantages over existing alternatives, including Bayer’s Stivarga® (regorafinib) and Taiho’s Lonsurf® (trifluridine and tipiracil). Bold Therapeutics expects to initiate a multinational pivotal Phase 3 randomized trial in 2024, with an accelerated approval expected in 2027, as well as numerous parallel Phase 2 trials in other solid and liquid tumor indications. Bold Therapeutics will be presenting as part of Canadian trade delegations at Bio Spain in Barcelona and BIO Europe in Munich in September and November, respectively, and is actively seeking development and commercialization partners for BOLD-100 in both Europe and Japan. Source: Bold Therapeutics Inc. Contact: E. Russell McAllister, CEO rm@bold-therapeutics.com

SEPTEMBER 12, 2023 Aktiv will blend Fitspace’s user-centric approach with immersive and engaging training spaces Aktiv Solutions, a functional fitness supply and design company, has acquired gym design and consulting firm Fitspace Design, the sides announced. Aktiv will integrate Fitspace Design’s user-centric approach with its premium training equipment and digital program offerings. Dave Greene, founder of Fitspace Design, remarked that Aktiv is a true leader in the commercial fitness space and is committed to innovation and results-driven facility design. “Together, we will set a new standard for helping commercial fitness operators of all types deliver the best possible experiences for their members and clients,” Greene said. Fitspace has a vast portfolio of fitness facility solutions, such as Renaissance Hotel Legacy West in Plano, Texas and The Creekview Corporate Fitness Center in Richardson, Texas. “We are excited to welcome Fitspace Design to the Aktiv team,” said Bryan Green, founder and CEO of Aktiv Solutions. “Dave Greene is a passionate orchestrator of modern gym design, and Fitspace’s expertise in user-centric function is perfectly aligned with our mission to create immersive and highly engaging training spaces.” Earlier this summer, Aktiv joined forces with Plunge, a rapidly growing cold water therapy brand featured on Shark Tank. The collaboration brings Plunge’s exhilarating treatments to fitness facilities and introduces its products to Aktiv’s commercial clients. Aktiv also expanded its functional training equipment line this summer with Gym Rax Forma, a strength-based system. The functional fitness supply and design company has also forged a successful partnership with boutique fitness franchisor Xponential, creating Xponential+ Training Bays so residents, students and employees can easily access the fitness franchisor’s ten brands outside of the studio.

This dynamic collaboration introduces PLUNGE’s premium and coveted cold water therapy products with Aktiv’s extensive commercial client base. Member Submission July 11, 2023 SANTA MONICA, CA—July 11, 2023—Aktiv Solutions, the leading expert in functional fitness facility supply and design, and PLUNGE, the innovative wellness brand that created the unique plunge product, announced today a collaboration to bring cold water recovery treatments to fitness facilities of all types. This dynamic collaboration introduces PLUNGE’s premium and coveted cold water therapy products with Aktiv’s extensive commercial client base; as recovery program and technology continues to emerge as a critical complement of the wellness experience. Aktiv’s design and planning expertise will now include guiding fitness facility operators and luxury home gym owners alike in their quest to expand the wellness space. “Aktiv is thrilled to partner with Plunge, a company that shares our passion for prioritizing recovery as a key component of wellness,” said Bryan Green, CEO and founder of Aktiv Solutions. “The demand for accessibility to cold water immersion in the fitness industry is growing rapidly, and we believe PLUNGE is the perfect partner to help expand the reach of our clients into this important category.” The partnership signifies the need to support the growing footprint of recovery training related space allocation in step with the rise is fitness activity. While the fitness industry has primarily focused on exercise and nutrition, giving equal attention to recovery is essential for achieving optimal results and improving overall health and well-being. Michael Garrett, co-founder of PLUNGE, expressed similar excitement, stating, “We are delighted to join forces with Aktiv Solutions to help integrate cutting edge spaces into fitness facilities looking to provide the tremendous benefits of cold water immersion to their clients. This is one further step in the advancement of making cold plunging as common as coffee. With Aktiv we can provide a greater level of collaboration with clients including leading hotels, corporations, and universities looking to expand their offerings in human wellness. It perfectly aligns with our ‘all boats rise’ concept and we are excited for the future.” About Aktiv Solutions  At Aktiv, we Design The Exercise Experience. Aktiv’s end-to-end solutions equip both commercial and residential fitness spaces with premium equipment and digital guidance powering today’s most sought after workouts. Our hero brand GYM RAX is the world’s leading fitness rigging solution for modular storage and equipment suspension.  Integrating the principles of functional fitness with the technical expertise of functional design is our calling. Aktiv’s mission is to establish safe and engaging health clubs, boutique studios, hotel gyms, corporate fitness centers, multi-family amenities, and beyond, while our clients deliver inspirational exercise experiences. For more information, visit aktivsolutions.com.

VANCOUVER, BC, June 1, 2023 — Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, will be presenting positive interim results in advanced gastric and biliary tract cancer at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2-6, 2023 in Chicago, Illinois. These results will be presented in the Gastrointestinal (Gastroesophageal, Pancreatic and Hepatobiliary) Cancer session on June 5, 2023 from 8:00AM – 12:00PM CT as Poster 4098: “BOLD-100-001 (TRIO039): A Phase 1b/2a Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Pre-Treated Advanced Gastric and Biliary Tract Cancer: Efficacy and Safety Analysis.” This poster includes progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) data in gastric and biliary tract cancer and expands on data in metastatic colorectal cancer presented earlier this year at the American Association for Cancer Research (AACR) 2023 conference. With compelling interim Phase 2 data in three different difficult-to-treat oncology indications (colorectal, gastric, and biliary tract), BOLD-100’s disruptive therapeutic potential is becoming increasingly evident. BOLD-100 is currently being studied in a global Phase 1b/2 trial for the treatment of advanced gastrointestinal cancers, with 110 patients successfully treated to date. Phase 1b trial results, presented at ASCO 2022, demonstrated that BOLD-100 in combination with FOLFOX was generally safe and well-tolerated. Interim Phase 2 data in metastatic colorectal cancer presented at AACR 2023 indicated that patients treated with BOLD-100 and FOLFOX showed a median PFS of 4.7 months, OS of 9.8 months, ORR of 13%, and DCR of 87%, substantially higher than standard-of-care data (Bayer’s Stivarga® and Taiho’s Lonsurf®) for a similar patient population which showed a median PFS of up to 2.0 months, OS of up to 7.1 months, ORR of up to 1.6%, and DCR of up to 44%. In addition, BOLD-100 in combination with FOLFOX proved to be exceptionally well-tolerated, with no new safety signals, and with patients remaining on therapy for up to 15 treatment cycles. Data from the full Phase 2 trial, which will include an additional 20 patients with advanced colorectal cancer, should be available in late 2023. Bold Therapeutics’ BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest. Collectively, these effects result in cell death in both sensitive and resistant cancers, giving BOLD-100 the potential to significantly improve outcomes in a wide range of both solid and liquid tumors in combination with other anticancer therapies ranging from traditional chemotherapies to targeted therapies and immuno-oncology agents. BOLD-100 was previously granted orphan drug designations (ODDs) in gastric and pancreatic cancer and expects additional ODDs and/or breakthrough therapy designations (BTDs) expected in 2023 and 2024. Bold Therapeutics is preparing to initiate a pivotal Phase 3 trial for BOLD-100 in the treatment of advanced colorectal cancer in 2024 and is currently evaluating potentially synergistic development and commercialization partnerships to support these efforts. Concurrently, Bold Therapeutics is exploring additional development indications for BOLD-100 while also advancing its pipeline of other novel metallotherapeutics. Additional information on ASCO https://conferences.asco.org/am/attend For more information, please visit the Company’s website at https://www.bold-therapeutics.com/ Source: Bold Therapeutics Inc. Contact: E. Russell McAllister, CEO rm@bold-therapeutics.com

VANCOUVER, BC, April 18, 2023 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim results from a Phase 2 clinical trial evaluating BOLD-100 in combination with standard-of-care chemotherapy for the treatment of advanced colorectal cancer at the American Association for Cancer Research (AACR) 2023 conference. Bold Therapeutics’ BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest. Collectively, these effects result in cell death in both sensitive and resistant cancers, giving BOLD-100 the potential to significantly improve outcomes in a wide range of both solid and liquid tumors in combination with other anticancer therapies ranging from traditional chemotherapies to targeted therapies and immuno-oncology agents. Earlier preclinical data showed that BOLD-100 has potential immune modulating capabilities, including the induction of immunogenic cell death pathways. Preclinical data presented concurrently at AACR 2023 in a translational research poster (#2259) entitled “Novel Metallotherapeutic BOLD-100 Induces Circulating Cytokine Changes When Administered in Combination with FOLFOX in Advanced Gastrointestinal Cancer Patients,” show that BOLD-100 in combination with FOLFOX induced short-term plasma level changes in multiple cytokines, including IL-10 and IL-27, which help explain BOLD-100’s synergistic activity with a wide range of other anti-cancer drugs. Bold Therapeutics’ ongoing multinational Phase 1b/2 trial (NCT04421820) evaluates BOLD-100 in combination with FOLFOX (folinic acid / leucovorin, fluorouracil, and oxaliplatin) in patients with advanced gastrointestinal cancers. The trial has currently enrolled 106 patients with advanced gastrointestinal (bile duct, colorectal, gastric, and pancreatic) cancers at sites in Canada, the United States, Ireland and South Korea, and the primary endpoint for the trial was progression-free survival (PFS), with overall survival (OS) and overall response rate (ORR) as secondary endpoints. Disease control rate (DCR) was also captured. Data from 17 patients with advanced metastatic colorectal cancer was presented in clinical poster (#CT149) entitled “BOLD-100-001 (TRIO039): a Phase 1b/2a Dose-Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Pre-treated Advanced Colorectal Cancer: Interim Efficacy, Safety and Tolerability Analysis.” Patients were treated with BOLD-100 and FOLFOX, and the results from this difficult-to-treat patient group showed a median PFS of 4.7 months, OS of 9.8 months, ORR of 13%, and DCR of 87%, substantially higher than standard-of-care data (Bayer’s Stivarga® and Taiho’s Lonsurf®) for a similar patient population which showed a median PFS of up to 2.0 months, OS of up to 7.1 months, ORR of up to 1.6%, and DCR of up to 44%, with some of the most remarkable outcomes for BOLD-100 in late-line patients that had previously failed on FOLFOX alone. In addition, BOLD-100 in combination with FOLFOX proved to be exceptionally well-tolerated, with no new safety signals, with patients remaining on therapy for up to 15 treatment cycles.     “We are extremely pleased to announce this positive interim Phase 2 data at AACR and look forward to sharing even more clinical data in the coming months at ASCO. These results clearly demonstrate that BOLD-100 has the potential to significantly improve treatment outcomes in both solid and liquid tumors, beginning with advanced colorectal cancer, one of the most difficult-to-treat solid tumor indications” said E. Russell McAllister, CEO of Bold Therapeutics. “Perhaps most importantly, these results were achieved with a safety and tolerability profile that is almost indistinguishable from FOLFOX alone.” Interim Phase 2 results in bile duct and gastric cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) conference in June, and data from the full Phase 2 trial, which will include an additional 20 patients with advanced colorectal cancer, should be available in late 2023. BOLD-100 was previously granted orphan drug designations (ODDs) in gastric and pancreatic cancer and expects additional ODDs and/or breakthrough therapy designations (BTDs) expected in 2023 and 2024. With a posterior probability of beating standard-of-care of 100% in PFS and 83% in OS in a head-to-head trial, Bold Therapeutics expects to initiate a pivotal Phase 3 trial for BOLD-100 in the treatment of advanced colorectal cancer in the near future and is currently evaluating potentially synergistic global development and commercialization partnerships. Concurrently, Bold Therapeutics is exploring additional development indications for BOLD-100 while also advancing its pipeline of other novel metallotherapeutics. For more information, please visit Bold Therapeutics’ website at www.bold-therapeutics.com. Additional information on AACR https://www.aacr.org/meeting/aacr-annual-meeting-2023/ Contact: E. Russell McAllister, CEO(604) 262-9899357453@email4pr.com SOURCE Bold Therapeutics Inc.

ATLANTA, April 18, 2022 /PRNewswire/ — Eagle Merchant Partners (Eagle), an Atlanta-based private equity firm specializing in franchise, multi-unit consumer and industrial middle market opportunities, has made an investment in Enviro-Master Services. An award-winning franchisor of deep cleaning services, Enviro-Master serves tens of thousands of businesses across North America. Its expertise in the health and safety industry and the techniques developed by the company helps to protects its clients and communities against the spread of dangerous bacteria and pathogens, including COVID-19. “The health and safety industry has grown exceptionally over the past several years and COVID-19 has accelerated that growth,” said Zack Taylor of Eagle Merchant Partners. “This partnership will enable Enviro-Master Services to scale up to meet this demand. We are thrilled to be working with the team.” The Charlotte, North Carolina-based company provides deep cleaning, sanitation, disinfection, and electrostatic spray services, along with hygienic products such as hand soap, hand sanitizers, and paper products. It focuses on the restaurant, convenience store, consumer retail, hospitality, commercial and industrial industries, servicing more than 250 brands representing more than 30,000 retail and restaurant locations nationwide. Named one of the fastest-growing private companies by Inc. magazine several years running, Enviro-Master has expanded to nearly 90 locations across the United States and Canada. Enviro-Master Services represents the tenth franchise investment made by Eagle and its principals. It has made several strategic investments in franchisors, franchisees and corporate owned multi-unit operators, including Code Ninjas, the world’s largest and fastest-growing coding franchise system for children. Inc. magazine named Eagle Merchant Partners one of the best private equity firms for entrepreneurs and founders. It invests in lower middle-market businesses. King & Spalding served as legal advisor to Eagle Merchant Partners. Croft & Bender and DLA Piper served as financial and legal advisors to Enviro-Master. ABOUT EAGLE MERCHANT PARTNERSEagle Merchant Partners is an Atlanta-based private equity firm focused on investments in Southeastern companies with unique growth opportunities. The partnership is one of the region’s most experienced private equity investors, investing in sixteen companies with more than $1.5 billion in revenues. For more information, visit eaglemerchantpartners.com. Media ContactThornton Kennedy404-210-0363thornton@prsouth.net SOURCE Eagle Merchant Partners

Vancouver BC – March 1, 2022- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that  they have successfully completed the Phase 1b (dose-escalation) portion of its seamless adaptive oncology trial  of BOLD-100 in combination with FOLFOX in the treatment of advanced gastrointestinal cancers (colorectal,  pancreatic, gastric and bile duct). BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein  response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes  DNA damage and cell cycle arrest. Collectively, these effects result in cell death in both sensitive and resistant  solid and liquid cancers and in combination with a wide range of existing anti-cancer therapies. The FDA  previously granted BOLD-100 Orphan Drug Designations (ODDs) in both Gastric and Pancreatic cancers, and  Bold Therapeutics anticipates leveraging clinical data from the Phase 1b portion of its trial for one or more  Breakthrough Therapy Designations (BTDs) in 2022. The Phase 1b data – which Bold Therapeutics anticipates presenting at an upcoming cancer conference – indicate that (1) BOLD-100 can be safely combined with FOLFOX chemotherapy at a dose of 625 mg / m2 (the highest dose level tested), with no new Grade 3 or 4 treatment-emergent adverse events; and (2) patients can safely remain on treatment for an extended number of treatment cycles. Based on this strong safety and tolerability profile, the Study Steering Committee unanimously endorsed proceeding immediately into the Phase 2 (dose-expansion) portion of the study. “Completing our Phase 1b trial with a strong safety profile for BOLD-100 is a significant achievement for Bold  Therapeutics – and while it is too early to say anything definitive, preliminary efficacy data is undoubtedly  encouraging,” said Jim Pankovich, EVP, Clinical Development. “Despite substantial headwinds from the ongoing  COVID-19 pandemic, we were nevertheless able to successfully enroll and treat patients at our six clinical sites  in Canada, and I wish to recognize the patients for their contribution to this study as well as the persistent and  resilient efforts of our investigators.” The Phase 2 (dose-expansion) portion of the seamless adaptive trial of BOLD-100 will enroll 80 additional  patients at 13 investigational sites worldwide: 6 sites in Canada; 2 sites in the U.S.; and 5 sites in South Korea.  Interim and complete Phase 2 data is expected by year-end 2022 and late 2023, respectively. “As BOLD-100 advances into Phase 2, Bold Therapeutics crosses another significant value inflection point,”  stated Glenn Walthall, Chief Investment Officer of Gaston Capital and Chairman of the Board of Bold  Therapeutics. “As Bold Therapeutics’ largest institutional investor, we are encouraged with the results that  we’ve seen thus far and optimistic that BOLD-100 may significantly improve outcomes in these difficult-to-treat  cancers that are often refractory to conventional treatment options. Consistent with preclinical observations, a  number of patients in the study who had previously failed on FOLFOX alone suddenly responded when BOLD 100 was added to the treatment regimen – a result that can only be described as remarkable.” Bold Therapeutics executed a regional option agreement with Hana Pharm in South Korea in 2020 and is  actively seeking development partners in other territories. Bold Therapeutics is also seeking investors for a  data-driven institutional Series B round to be closed later in 2022, likely concurrent with interim Phase 2 results. “I am exceptionally proud of the agile and industrious Bold Therapeutics team without whom this success would  not be possible,” added E. Russell McAllister, CEO of Bold Therapeutics. “Through innovative programs like NRC IRAP, the Canadian government has provided Bold Therapeutics with substantial support in advancing our  scientific understanding of BOLD-100 that not only allowed us to advance in the treatment of gastrointestinal cancer indications, but also opened up promising areas for future development. As a result, they share this win  with us. The strong results from this Phase 1b trial and the overall accumulation of data on BOLD-100 continue  to excite support for the development of this innovative therapeutic for patients with a wide range of advanced  cancers.” Additional information on this study is available at https://www.clinicaltrials.gov/ct2/show/NCT04421820 For more information, please visit the Company’s website at https://www.bold-therapeutics.com/  Source: Bold Therapeutics Inc. Contact: E. Russell McAllister, CEO rm@bold-therapeutics.com (604) 262-9899